NeoGenomics, Inc. (NEO) News
Filter NEO News Items
NEO News Results
|Loading, please wait...|
NEO News Highlights
- For NEO, its 30 day story count is now at 17.
- Over the past 20 days, the trend for NEO's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about NEO are BEAT, ROSE and ARQQ.
Latest NEO News From Around the Web
Below are the latest news stories about NEOGENOMICS INC that investors may wish to consider to help them evaluate NEO as an investment opportunity.
RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
NeoGenomics, Inc. (NASDAQ:NEO),a leading provider of oncology testing and global contract research services, and its liquid biopsy-focused subsidiary, Inivata Limited ("Inivata") today announced that new data, being presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, support the use of the RaDaR®Assay across all types of early breast cancer in both the adjuvant and surveillance settings.
NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
NeoGenomics, Inc. (NASDAQ:NEO),a leading provider of oncology testing and global contract research services, today launched a novel biomarker testing program for patients with epithelial ovarian cancer, including primary peritoneal or fallopian tube cancers (EOC).Through the FR-ASSIST™ program, sponsored by ImmunoGen, Inc., (Nasdaq:IMGN), EOC patients will have access to the FOLR1 IHC CDx test (VENTANA FOLR1 RxDx Assay) performed by NeoGenomics to
Raymond James analyst Andrew Cooper maintained a Buy rating on NeoGenomics (NEO - Research Report) today and set a price target of $12.00. The company's shares closed yesterday at $10.08.According to TipRanks, Cooper is an analyst with an average return of -21.5% and a 27.08% success rate. Cooper covers the Healthcare sector, focusing on stocks such as LumiraDx, Exact Sciences, and Haemonetics.In addition to Raymond James, NeoGenomics also received a Buy from Goldman Sachs's Matthew Sykes in a report issued on November 9. However, on the same day, Morgan Stanley maintained a Hold rating on NeoGenomics (NASDAQ: NEO).
The cancer screening company showed its turnaround may be working.
NeoGenomics ( NASDAQ:NEO ) Third Quarter 2022 Results Key Financial Results Revenue: US$128.8m (up 6.1% from 3Q 2021...
U.S. stocks closed higher on Tuesday, with the Dow Jones surging more than 300 points. Here is the list of some big stocks recording gains in the previous session. TaskUs, Inc. (NASDAQ: TASK ) shares climbed 37.2% to settle at $22.01 on Tuesday after the company reported better-than-expected Q3 results. The company also issued Q4 and FY22 sales guidance above analyst estimates. SkyWater Technology, Inc. (NASDAQ: SKYT ) surged 31.6% to close at $11.37 after the company reported better-than-expected Q3 EPS and sales results. Groupon, Inc. (NASDAQ: GRPN ) rose 27.4% to settle at $8.97 following Q3 results. NeoGenomics, Inc. (NASDAQ: NEO ) climbed 25.4% to close at $8.90 following better-than-expected Q3 results. Arqit Quantum Inc. (NASDAQ: ARQQ ) gained 25% to close at $10.26. LivePerson, ...
The following slide deck was published by NeoGenomics, Inc.
NeoGenomics, Inc. (NASDAQ:NASDAQ:NEO) Q3 2022 Results Conference Call November 08, 2022 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Bill Bonello - Chief Financial…
NeoGenomics (NEO) stock rose ~28% on Tuesday after Q3 results beat estimates.Adjusted net loss widened to -$17.9M, compared to -$9.77M in Q3 2021.Total net revenue grew +6.13% Y/Y…